Skip to main content
SpringerLink
Log in

Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background and Aim

Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3.

Methods

We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups.

Results

The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5%) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively).

Conclusions

In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.

    Article  CAS  Google Scholar 

  2. Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001–2201.

    PubMed  Google Scholar 

  3. Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49:177–183.

    Article  Google Scholar 

  4. Zhang CK, Hewett J, Hemming J, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1732–1739.

    Article  Google Scholar 

  5. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.

    Article  CAS  Google Scholar 

  6. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.

    Article  CAS  Google Scholar 

  7. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789–799.

    Article  Google Scholar 

  8. Katz J. The course of inflammatory bowel disease. Med Clin N Am. 1994;78:1275–1280.

    Article  CAS  Google Scholar 

  9. Sahami S, Konte K, Buskens CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United Eur Gastroenterol J. 2017;5:554–562.

    Article  CAS  Google Scholar 

  10. Eszter Muller K, Laszlo Lakatos P, Papp M, et al. Incidence and paris classification of pediatric inflammatory bowel disease. Gastroenterol Res Pract. 2014;2014:904307.

    Article  Google Scholar 

  11. Muller KE, Lakatos PL, Arato A, et al. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:576–582.

    Article  Google Scholar 

  12. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209.

    Article  CAS  Google Scholar 

  13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.

    Article  CAS  Google Scholar 

  14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.

    Article  CAS  Google Scholar 

  15. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.

    Article  Google Scholar 

  16. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.

    Article  Google Scholar 

  17. O’Morain C, Tobin A, Leen E, et al. Criteria of case definition in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7–11. discussion 16–19.

    Article  Google Scholar 

  18. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn’s disease. Dig Dis Sci. 2007;52:2063–2068. https://doi.org/10.1007/s10620-006-9691-2

    Article  PubMed  Google Scholar 

  19. Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol. 1988;10:41–45.

    Article  CAS  Google Scholar 

  20. Lee JH, Cheon JH, Kim ES, et al. The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. Dig Dis Sci. 2010;55:1406–1412. https://doi.org/10.1007/s10620-009-0847-8

    Article  PubMed  Google Scholar 

  21. Park SH, Loftus EV Jr, Yang SK. Appendiceal skip inflammation and ulcerative colitis. Dig Dis Sci. 2014;59:2050–2057. https://doi.org/10.1007/s10620-014-3129-z

    Article  CAS  PubMed  Google Scholar 

  22. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44:431–440.

    Article  Google Scholar 

  23. Abdalla M, Landerholm K, Andersson P, et al. Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study. Clin Gastroenterol Hepatol. 2017;15:1055.e1052–1060.e1052.

    Article  Google Scholar 

  24. Myrelid P, Landerholm K, Nordenvall C, et al. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–1319.

    Article  Google Scholar 

  25. Fukuda T, Naganuma M, Sugimoto S, et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: a report from the IBD registry. PLoS ONE. 2017;12:e0187737.

    Article  Google Scholar 

  26. Park BJ, Lee KJ, Hwang JC, et al. Relapse rates of ulcerative colitis in remission and factors related to relapse. Korean J Gastroenterol. 2008;52:21–26.

    PubMed  Google Scholar 

  27. Mudireddy P, Scott F, Feathers A, et al. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. Inflamm Bowel Dis. 2017;23:1832–1839.

    Article  Google Scholar 

Download references

Acknowledgments

Funding was provided by Ministry of Health and Welfare (Grant No. HI14C1324) and Ministry of Science, ICT and Future Planning (Grant No. NRF-2017R1A2B4001848).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea

    Dong Suk Shin, Jae Hee Cheon, Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim & Won Ho Kim

  2. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

    Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim & Won Ho Kim

Authors
  1. Dong Suk Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Hee Cheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Eun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yehyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soo Jung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tae Il Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Won Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dong Suk Shin was involved in acquisition of data, analysis and interpretation of data, and drafting of the manuscript. Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, and Won Ho Kim were responsible for the study concept and design and for critical revision of the manuscript for important intellectual content. Jae Hee Cheon was involved in acquisition of data, study concept and design, and critical revision of the manuscript for important intellectual content. All authors approved the final version of the article, including the authorship list.

Corresponding author

Correspondence to Jae Hee Cheon.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 1136 kb)

Supplementary material 2 (TIFF 1065 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, D.S., Cheon, J.H., Park, Y.E. et al. Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis. Dig Dis Sci 63, 3097–3104 (2018). https://doi.org/10.1007/s10620-018-5218-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-018-5218-x

Keywords

Search

Navigation